Skip to main content

Table 1 Particular aspects of the clinical diagnosis for each control and HB-19 treated RET mice

From: Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice

Treatment

 

Remarks in mice before autopsy (< Day 300)

Diagnosis at autopsy (Day 300)

 
 

Mice

Regression

Death

Cutaneous tumor location and size (mm)

Distant metastasis

Control

1

  

under eye 4, nose 3.1, under ear 4.9, back 6.7, 2.8 and 2.9, thigh 5.9

Mediastinal

 

2

  

cheek 4.9, eye 6.2, under ear 5.4, 6.2, 7 and 5.7, back 6.3 and 4.2, around genitals 3.8 and 4.7

None

 

3

  

cheek 3.3, under ear 6.7, around eye 6.3, back ear 3.5, back 3.2, thigh 5.1

Retroperitoneal

 

4

  

under eye 6.7 and 2.3, cheek 4.1 and 3, upper ear 2.8, under ear 3.4 and 5.6, leg 4.9 and 4.3, genitals 4

Retroperitoneal

 

5

  

under eye 11, 4 leg neighboring nodules 13.9

Visceral

 

6

  

upper eye 6.3, under eye 2.6, between ears 5.4

Retroperitoneal

 

7

  

cheek 2.9, nose 4.3, under ear 3.8, ear 4.7

Retroperitoneal

 

8

  

cheek 3.1, under eye 2.7

None

 

9

  

under ear 2.5, between eyes 3.8, under eye 6.3 and 3, leg 6.8, genitals 5.5, tail base 5.9

Retroperitoneal

 

10

  

cheek 5.6, 5.1, 3.4 and 3.7, under eye 7.4, leg 4.7, thigh 11.3

None

 

11

  

back ears 4.9, back 2.8, 1.9, 6.4, 3.5 and 2.2

Retroperitonel

HB-19 treated

1

  

under eye 6, cheek 3.5, around left eye 7.7, between ears 5, genitals 8, foot 9.2, tail 3.6

Visceral

 

2

under eye and thigh

 

cheek 5.2 and 3, under eye 5, 3 nodules on the left cheek < 1, between ears 8.2, thigh 8.2, foot 7.9

Visceral

 

3

  

cheek 2.5, under ear 5.7, back 9.6, 5.5 and 3.2, thigh 6

Lung

 

4

  

Tumor free mouse

None

 

5

 

dead D219*

Tumor free mouse at day 219

None

 

6

  

Tumor free mouse

None

 

7

  

cheek 1.4, under eye 3.9, back ears 6.4

None

 

8

  

under eye 3.9, under ear 4.7, back 1.5, tail base 2.3

None

 

9

  

around eye 6.7

None

  1. The particular aspects of the clinical diagnosis for the control (n = 11) and HB-19 treated (n = 9) RET mice are presented individually for each mouse. Column "Remarks in mice before autopsy" before day 300 gives tumor regression and natural death that occurred in HB-19 treated mouse 2 and 5, respectively. Column "Diagnosis at autopsy" at day 300 gives the location of cutaneous tumors and their size measured with a caliper (the numbers next to each location correspond to the size of the tumor mass in mm), and metastasis occuring at distant locations, i.e., visceral metastasis as well as mediastinal adenopathies or lung metastasis (column "Distant metastasis"). Such non-cutaneous tumors were all chracterized by a large tumor mass (> 4 mm).
  2. * Mouse N°5 died spontaneously at day 219 without symptoms of melanoma.